Journal
INFECTION AND IMMUNITY
Volume 72, Issue 8, Pages 4810-4818Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/IAI.72.8.4810-4818.2004
Keywords
-
Categories
Funding
- NIAID NIH HHS [F31 AI010129, R01 AI035370, R01 AI045459, R01AI045459, R01AI035370, R01 AI044374, R01AI044374] Funding Source: Medline
Ask authors/readers for more resources
The features of protective murine antibodies to the Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) have been rigorously investigated; however, the characteristics of protective human antibodies to GXM have not been defined. We produced monoclonal antibodies (MAbs) from XenoMouse mice (transgenic mice that express human immunoglobulin M [IgM], IgG2, and K) which were immunized with a C neoformans serotype D strain 24067 GXM-diphtheria toxoid conjugate. This study reports the specificity and efficacy of three human IgM MAbs, G14, G15, and G19, generated from these mice. Each MAb was specific for GXM, but G14 and G19 had different specificity based on their binding to serotype A strain H99 and SB4 GXMs, to which G15 did not bind. Nucleic acid sequence analysis revealed that G15 uses V(H)3-64 in the germ line configuration. G14 and G19 use V(H)6-1, which has somatic mutations. All of the MAbs use Vkappa DPK22/A27. Studies of MAb efficacy in BALB/c mice showed that administration of 0.1 mg, but not 1 or 0.01 mg, of G15 prolonged survival against lethal C neoformans strain 24067 challenge, whereas G14 and G19 were not protective at any dose. This panel of MAbs illustrates that serotype D GXM has epitopes that elicit human antibodies that can be either protective or nonprotective. Our findings suggest that V-H gene use may influence GXM specificity and efficacy, and they provide insights into the possible contribution that V-H gene use may have in resistance and susceptibility to cryptococcosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available